F 0605
Level of Harm - Minimal harm
or potential for actual harm
Residents Affected - Few
Prevent the use of unnecessary psychotropic medications or use medications that may restrain a resident's
ability to function.
Based on clinical record review, facility policy, and staff interview, it was determined that the facility failed to
ensure that residents medication regimen was free from unnecessary psychotropic medication for two of
seven residents reviewed for unnecessary medications (Residents R1, and R47).
Findings include:
Review of facility policy titled Psychotropic Medication Use (revised 2024), revealed psychotropic
medications is any medication that affects brain activity associated with mental processes and behavior.
Psychotropic medications are not prescribed or administered on a PRN (as needed) basis unless the
medication is necessary to treat a diagnosed specific condition that is documented in the clinical record.
PRN orders for psychotropic medications are limited to 14 days. For psychotropic medications that are not
antipsychotics: if the prescriber or attending physician believes it is appropriate to extend the PRN order
beyond 14 days, they will document the rationale for extending the use and include the duration for the PRN
order.
Clinical record review revealed Resident R1 was admitted to the facility November 15, 2024 with a
diagnosis that included chronic respiratory failure, multiple sclerosis (breakdown of the protective covering
of nerves), and cognitive communication deficit.
Review of Resident R1's physician's order, dated March 25, 2025, revealed an order for Clonazepam
(psychotropic anti-anxiety medication) 1 mg (milligram) every 24 hours as needed for anxiety/insomnia.
Give PRN at bedtime.
Further review of physician's order for Clonazepam 1 mg revealed a stop date of indefinite.
Review of Resident R1's clinical record revealed physician's order for PRN Clonazepam 1 mg was ordered
for anxiety/insomnia. Resident R1 had no documented diagnosis for anxiety/insomnia.
Clinical record review revealed Resident R47 was admitted to the facility November 18, 2024 with a
diagnosis that included chronic respiratory failure, anoxic brain damage (brain is deprived by oxygen), and
dysphagia.
Review of Resident R47's physician's order, dated April 14, 2025, revealed an order for Ativan
(psychotropic anti-anxiety medication) 0.5 mg every 8 hours as needed for teeth grinding.
Further review of physician's order for Ativan 0.5 mg revealed a stop date of indefinite.
(continued on next page)
Any deficiency statement ending with an asterisk (*) denotes a deficiency which the institution may be excused from correcting providing it is determined that other
safeguards provide sufficient protection to the patients. (See instructions.) Except for nursing homes, the findings stated above are disclosable 90 days following the
date of survey whether or not a plan of correction is provided. For nursing homes, the above findings and plans of correction are disclosable 14 days following the date
these documents are made available to the facility. If deficiencies are cited, an approved plan of correction is requisite to continued program participation.
LABORATORY DIRECTOR'S OR PROVIDER/SUPPLIER
REPRESENTATIVE'S SIGNATURE
TITLE
(X6) DATE
FORM CMS-2567 (02/99)
Previous Versions Obsolete
Facility ID:
If continuation sheet
Page 1 of 6
Event ID:
395847
Printed: 05/15/2026
Form Approved OMB
No. 0938-0391
Department of Health & Human Services
Centers for Medicare & Medicaid Services
STATEMENT OF DEFICIENCIES
AND PLAN OF CORRECTION
(X1) PROVIDER/SUPPLIER/CLIA
IDENTIFICATION NUMBER:
(X2) MULTIPLE CONSTRUCTION
395847
B. Wing
A. Building
(X3) DATE SURVEY
COMPLETED
05/09/2025
NAME OF PROVIDER OR SUPPLIER
STREET ADDRESS, CITY, STATE, ZIP CODE
Montgomery Subacute and Respiratory Center
251 Stenton Avenue
Plymouth Meeting, PA 19462
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.
(X4) ID PREFIX TAG
SUMMARY STATEMENT OF DEFICIENCIES
(Each deficiency must be preceded by full regulatory or LSC identifying information)
F 0605
Level of Harm - Minimal harm
or potential for actual harm
Residents Affected - Few
Review of Resident R47's clinical record revealed physician's order for as needed Ativan 0.5 mg was
ordered for teeth grinding. Resident R47 had no documented diagnosis for teeth grinding.
The facility failed to ensure psychotropic medication was used to treat a specific condition as diagnosed
and documented in the clinical record and failed to ensure as needed psychotropic medication was limited
to 14 days or a clinical rationale for continuing beyond 14 days.
28 Pa. Code 211.2(d)(3) Medical director
28 Pa. Code 211.12(d)(1)(3)(5) Nursing services
FORM CMS-2567 (02/99)
Previous Versions Obsolete
Event ID:
Facility ID:
395847
If continuation sheet
Page 2 of 6
Printed: 05/15/2026
Form Approved OMB
No. 0938-0391
Department of Health & Human Services
Centers for Medicare & Medicaid Services
STATEMENT OF DEFICIENCIES
AND PLAN OF CORRECTION
(X1) PROVIDER/SUPPLIER/CLIA
IDENTIFICATION NUMBER:
(X2) MULTIPLE CONSTRUCTION
395847
B. Wing
A. Building
(X3) DATE SURVEY
COMPLETED
05/09/2025
NAME OF PROVIDER OR SUPPLIER
STREET ADDRESS, CITY, STATE, ZIP CODE
Montgomery Subacute and Respiratory Center
251 Stenton Avenue
Plymouth Meeting, PA 19462
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.
(X4) ID PREFIX TAG
SUMMARY STATEMENT OF DEFICIENCIES
(Each deficiency must be preceded by full regulatory or LSC identifying information)
F 0697
Provide safe, appropriate pain management for a resident who requires such services.
Level of Harm - Minimal harm
or potential for actual harm
Based on review of clinical records, facility documentation, and staff interviews, it was determined that the
facility failed to administer pain medication in accordance with physician orders for two of four residents
reviewed for pain management (Residents R11, and R29).
Residents Affected - Few
Findings include:
Review of facility policy titled Pain Assessment and Management, revised 2025, stated pain is a
multidisciplinary process that includes the following: developing and implementing approaches to pain
management based on accepted standards of practice. The medication regimen is implemented as
ordered. Results of the interventions are documented and communicated directly to the provider when
appropriate. Ongoing communication between the prescriber and the staff is necessary for the optimal and
judicious use of pain medications.
Clinical record review revealed Resident R11 was admitted to the facility December 20, 2018 with a
diagnosis that included chronic repository failure, anoxic brain damage (brain is deprived of oxygen), and
pain.
Review of Resident R11's physician's order, dated April 09, 2025, revealed an order for Oxycodone (opiod
for moderate to severe pain) 2.5 mg (milligrams) every 8 hours as needed for moderate to severe pain for
pain level of 7-10 (on a pain scale of 1-10 with 1 being the least pain and 10 the most severe pain).
Review of two months of Resident R11's medication administration record revealed Oxycodone 2.5 mg was
administered for the following pain levels:
-April 18, 2025 at 10:22 a.m. pain level of 6.
-April 21, 2024 at 2:20 p.m. pain level of 5.
-April 22, 2025 at 11:00 a.m. pain level of 5.
-April 25, 2025 at 11:24 a.m. pain level of 5.
-May 1, 2025 at 1:00 p.m. pain level of 6.
-May 06, 2025 at 1:53 a.m. pain level of 5.
Clinical Record review revealed Resident R29 was admitted to the facility June 17, 2020 with a diagnosis
that included chronic respiratory failure, cerebral infarctionv (blood supply to part of the brain is blocked or
reduced), and pain.
Review of Resident R29's physician's order, dated April 12, 2025, revealed an order for
Oxycodone-Acetaminophen 5-325 mg tablet, 2 tablets by mouth every 6 hours as needed for severe pain
for pain level of 6-10.
Review of two months of Resident R29's medication administration record revealed
Oxycodone-Acetaminophen 5-325 mg tablet, 2 tablets was administered for the following pain levels:
(continued on next page)
FORM CMS-2567 (02/99)
Previous Versions Obsolete
Event ID:
Facility ID:
395847
If continuation sheet
Page 3 of 6
Printed: 05/15/2026
Form Approved OMB
No. 0938-0391
Department of Health & Human Services
Centers for Medicare & Medicaid Services
STATEMENT OF DEFICIENCIES
AND PLAN OF CORRECTION
(X1) PROVIDER/SUPPLIER/CLIA
IDENTIFICATION NUMBER:
(X2) MULTIPLE CONSTRUCTION
395847
B. Wing
A. Building
(X3) DATE SURVEY
COMPLETED
05/09/2025
NAME OF PROVIDER OR SUPPLIER
STREET ADDRESS, CITY, STATE, ZIP CODE
Montgomery Subacute and Respiratory Center
251 Stenton Avenue
Plymouth Meeting, PA 19462
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.
(X4) ID PREFIX TAG
SUMMARY STATEMENT OF DEFICIENCIES
(Each deficiency must be preceded by full regulatory or LSC identifying information)
F 0697
-April 28, 2025 at 8:14 a.m. pain level of 4.
Level of Harm - Minimal harm
or potential for actual harm
-April 29, 2025 at 10:26 p.m. pain level of 5.
Residents Affected - Few
Interview on May 7, 2025 at 2:07 p.m. with Director of Nursing, Employee E2, confirmed the facility staff
administered Resident R11's and Resident R29's pain medication outside of the parameters of the
physician's orders.
28 Pa Code 211.10(c) Resident care policies
28 Pa Code 211.12 (d)(5) Nursing services
FORM CMS-2567 (02/99)
Previous Versions Obsolete
Event ID:
Facility ID:
395847
If continuation sheet
Page 4 of 6
Printed: 05/15/2026
Form Approved OMB
No. 0938-0391
Department of Health & Human Services
Centers for Medicare & Medicaid Services
STATEMENT OF DEFICIENCIES
AND PLAN OF CORRECTION
(X1) PROVIDER/SUPPLIER/CLIA
IDENTIFICATION NUMBER:
(X2) MULTIPLE CONSTRUCTION
395847
B. Wing
A. Building
(X3) DATE SURVEY
COMPLETED
05/09/2025
NAME OF PROVIDER OR SUPPLIER
STREET ADDRESS, CITY, STATE, ZIP CODE
Montgomery Subacute and Respiratory Center
251 Stenton Avenue
Plymouth Meeting, PA 19462
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.
(X4) ID PREFIX TAG
SUMMARY STATEMENT OF DEFICIENCIES
(Each deficiency must be preceded by full regulatory or LSC identifying information)
F 0756
Level of Harm - Minimal harm
or potential for actual harm
Residents Affected - Few
Ensure a licensed pharmacist perform a monthly drug regimen review, including the medical chart,
following irregularity reporting guidelines in developed policies and procedures.
Based on review of facility policy, review of clinical records, and staff interview, it was determined that the
facility failed to ensure that the physician documented the pharmacist identified irregularities were reviewed
and failed to document the action taken or not taken to address irregularities for two of five residents
reviewed. (Resident R18 and resident R42)
Findings:
Review of facility policy titled Medication Regime Reviews revised February 2025, revealed a pharmacist
performs a medication regime review (MRR) for every resident in the facility receiving medication for the
purpose of promote positive outcomes while minimizing adverse consequences and potential risks
associated with the medication identified irregularities. The medication regime review (MRR) reports
including physician responses are maintained as a part of the permanent medical record. After receiving
the MMR report from the pharmacist, the attending physician reviews and responds to the report then
documents in the residence medical record that the pharmacist recommendations have been reviewed and
if any actions were taken to address them.
Review of Resident R18's quarterly MDS (Minimum Data Set - a mandatory periodic resident assessment
tool) dated April 13, 2025, revealed that the resident entered the facility March 6, 2025, and had diagnoses'
including diabetes (a disease in which the body's ability to produce or respond to the hormone insulin is
impaired, resulting in abnormal metabolism of carbohydrates and elevated levels of glucose), anemia (a
condition in which the blood does not have enough red blood cells to carry oxygen through the body),
hypotension (high blood pressure), quadriplegia(a condition that causes paralysis in a persons limbs) and
seizure disorder (an uncontrolled, abnormal electrical activity in the brain that can cause temporary
abnormalities in muscle tone or movements). Continued review revealed that the resident required
medications: insulin, antipsychotics, opiods antianxiety.
Review of resident's pharmacist recommendations dated January 6, 2025, revealed that the pharmacist
reported that Resident R18 wascurrently receiving zinc supplement and stated to please note that over
supplementation of zinc has been linked to gastrointestinal irritation, taste disturbance, and possible
decrease in healing and instructed to please evaluate the need and consider discontinuing zinc after two
weeks.
Further review of this pharmacy recommendation revealed that the recommendation document was not
signed or dated by a physician.
Continued review of pharmacist recommendation revealed that this recommendation to evaluate and
discontinues the supplement zinc was resubmitted February 7, 2025 and April 8, 2025, neither was signed
or dated by a physician and there was no evidence of evaluation or consideration of the supplement zinc
discontinued.
Review of Resident R42's quarterly MDS (Minimum Data Set - a mandatory periodic resident assessment
tool) dated February 25, 2025, revealed that the resident entered the facility May 23, 2024, with diagnosis'
including seizure disorder (a uncontrolled, abnormal electrical activity in the brain that can cause temporary
abnormalities in muscle tone or movements), anxiety, and depression.
Review of Resident R42's pharmacy recommendations dated April 5, 2025, revealed that Resident 42
(continued on next page)
FORM CMS-2567 (02/99)
Previous Versions Obsolete
Event ID:
Facility ID:
395847
If continuation sheet
Page 5 of 6
Printed: 05/15/2026
Form Approved OMB
No. 0938-0391
Department of Health & Human Services
Centers for Medicare & Medicaid Services
STATEMENT OF DEFICIENCIES
AND PLAN OF CORRECTION
(X1) PROVIDER/SUPPLIER/CLIA
IDENTIFICATION NUMBER:
(X2) MULTIPLE CONSTRUCTION
395847
B. Wing
A. Building
(X3) DATE SURVEY
COMPLETED
05/09/2025
NAME OF PROVIDER OR SUPPLIER
STREET ADDRESS, CITY, STATE, ZIP CODE
Montgomery Subacute and Respiratory Center
251 Stenton Avenue
Plymouth Meeting, PA 19462
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.
(X4) ID PREFIX TAG
SUMMARY STATEMENT OF DEFICIENCIES
(Each deficiency must be preceded by full regulatory or LSC identifying information)
F 0756
Level of Harm - Minimal harm
or potential for actual harm
was ordered Depakote (medication to treat seizures), and there was no Valproic acid level (Valproic acid
has a narrow therapeutic range, meaning the difference between a dose that is effective and one that is
potentially toxic is small) in the clinical record. It was suggested for Valproic level to be obtain to monitor
therapy. Continued review of this pharmacist recommendation document revealed the physician agreed,
signed and dated the document.
Residents Affected - Few
Review of Resident R42's clinical record revealed that there was no indication that any labs were ordered
or completed for resident 42's Valproic level to maintain medication therapy.
28 Pa. Code 211.9(k) Pharmacy services
28 Pa Code 211.12(c) Nursing services
FORM CMS-2567 (02/99)
Previous Versions Obsolete
Event ID:
Facility ID:
395847
If continuation sheet
Page 6 of 6